Article

Antiobesity drugs in the management of type 2 diabetes: A shift in thinking?

Bartolome Burguera, MD, PhD, Khawla F. Ali, MD and Juan P. Brito, MD
Cleveland Clinic Journal of Medicine July 2017, 84 (7 suppl 1) S39-S46; DOI: https://doi.org/10.3949/ccjm.84.s1.05

Article Information

vol. 84 no. 7 suppl 1 S39-S46
DOI 
https://doi.org/10.3949/ccjm.84.s1.05
PubMed 
28708481
Published By 
Cleveland Clinic Journal of Medicine
Print ISSN 
0891-1150
Online ISSN 
1939-2869
History 
  • Published online July 1, 2017.
Copyright & Usage 
Copyright © 2017 The Cleveland Clinic Foundation. All Rights Reserved.

Author Information

  1. Bartolome Burguera, MD, PhD⇑
  1. Director of Obesity Programs, Endocrinology & Metabolism Institute, Cleveland Clinic
  2. Professor, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH
  3. Medical Director, National Diabetes and Obesity Research Institute, Tradition, MS
  1. Correspondence:
    Bartolome Burguera, MD, PhD, Endocrinology and Metabolism Institute, F-20, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195; burgueb{at}ccf.org
  1. Khawla F. Ali, MD
  1. Endocrinology & Metabolism Institute, Cleveland Clinic
  1. Juan P. Brito, MD
  1. Division of Endocrinology, Assistant Professor of Medicine, Medical Director of the Shared Decision Making National Resource Center Investigator, Knowledge and Evaluation Research Unit, Mayo Clinc
  2. Department of Medicine, Mayo Clinic, Rochester, MN
Back to top

In this issue

Print
Download PDF
Article Alerts
Email Article
Citation Tools

Jump to section

Subjects